/ drug trial
Vertex (VRTX) Stock Climbs Premarket After Late-Stage Kidney Drug Success
Vertex Pharmaceuticals surged in premarket trading after its kidney disease drug povetacicept met the main goal in a late-stage trial.
March 10, 2026Vertex Pharmaceuticals surged in premarket trading after its kidney disease drug povetacicept met the main goal in a late-stage trial.
March 10, 2026